INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 51 filers reported holding INOZYME PHARMA INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,405,518 | -16.0% | 334,647 | +11.4% | 0.00% | – |
Q2 2023 | $1,673,133 | +536.4% | 300,383 | +554.7% | 0.00% | – |
Q1 2023 | $262,903 | +445.0% | 45,882 | -0.1% | 0.00% | – |
Q4 2022 | $48,240 | -55.3% | 45,943 | +14.0% | 0.00% | – |
Q3 2022 | $108,000 | -51.8% | 40,304 | -14.2% | 0.00% | – |
Q2 2022 | $224,000 | -51.9% | 46,990 | -58.7% | 0.00% | – |
Q1 2022 | $466,000 | -43.4% | 113,823 | -5.7% | 0.00% | – |
Q4 2021 | $823,000 | -38.8% | 120,762 | +4.0% | 0.00% | – |
Q3 2021 | $1,345,000 | -34.6% | 116,101 | -3.8% | 0.00% | – |
Q2 2021 | $2,057,000 | -10.0% | 120,743 | +4.6% | 0.00% | – |
Q1 2021 | $2,286,000 | +19.4% | 115,469 | +24.4% | 0.00% | – |
Q4 2020 | $1,915,000 | -21.5% | 92,806 | +0.0% | 0.00% | -100.0% |
Q3 2020 | $2,439,000 | – | 92,764 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Pivotal bioVenture Partners Investment Advisor LLC | 4,494,851 | $18,878,374 | 7.53% |
CHI Advisors LLC | 1,270,027 | $5,334,112 | 2.11% |
Samsara BioCapital, LLC | 1,562,500 | $6,562,500 | 2.01% |
Affinity Asset Advisors, LLC | 1,379,852 | $5,795,378 | 1.63% |
Sofinnova Investments, Inc. | 4,280,308 | $17,977,294 | 1.13% |
SPHERA FUNDS MANAGEMENT LTD. | 1,234,907 | $5,186,609 | 0.94% |
Octagon Capital Advisors LP | 1,300,000 | $5,460,000 | 0.84% |
NEA Management Company, LLC | 2,437,689 | $10,238,294 | 0.79% |
Knott David M Jr | 454,008 | $1,907 | 0.73% |
Rock Springs Capital Management LP | 3,681,174 | $15,460,931 | 0.41% |